Table 1 Demographic characteristics of the study participants
Variables | Findings | No | Percentage (%) |
|---|---|---|---|
Gender | Male | 6 | 19.4 |
Female | 25 | 80 | |
Age in years | 16–20 | 4 | 12.9 |
21–25 | 3 | 9.7 | |
26–30 | 3 | 9.7 | |
31–35 | 3 | 9.7 | |
36–40 | 1 | 3.2 | |
> 40 | 17 | 54.8 | |
Symptoms | Visual | 10 | 32.3 |
Motor | 21 | 67.7 | |
Visual status | Impairment of visual acuity | 1 | 10 |
Complete visual loss | 8 | 80 | |
Impairment of visual acuity & color vision | 1 | 10 | |
Disease duration since the onset | Days | 5 | 16.1 |
Weeks | 6 | 19.4 | |
Months | 10 | 32.3 | |
Years | 10 | 32.3 | |
Visual acuity | Blindness | 13 | 41.9 |
Normal | 12 | 38.7 | |
Impaired | 6 | 19.4 | |
Fundus examination | Optic atrophy | 22 | 71.0 |
Normal | 9 | 29.0 | |
Motor system findings | Paraparises | 6 | 19.4 |
Paraplegia | 16 | 51.6 | |
Quadriparesis | 4 | 12.9 | |
Quadriplegia | 5 | 16.1 | |
Complete improvement | 6 | 19.4 | |
Clinical course | Single relapse | 21 | 68 |
Relapsing | 10 | 32 | |
MRI brain | Normal | 23 | 74 |
Abnormal | 8 | 26 | |
MRI spinal cord | Normal | 2 | 6 |
Abnormal | 29 | 94 | |
CSF NMO-IgG | +Ve | 25 | 79 |
−Ve | 6 | 21 | |
Serum aquaporin-4 antibody | +Ve | 25 | 79 |
−Ve | 6 | 21 | |
Treatment | IV methylprednisolone followed by oral | 5 | 16 |
IV methylprednisolone followed by oral+ azathioprine | 26 | 84 | |
Outcomes | Complete improvement | 2 | 6 |
Improvement with disability | 22 | 71 | |
No improvement | 7 | 23 |